Regular Quarterly Dividend of $0.35 per Share and Supplemental Quarterly Dividend of $0.01 per Share Payable May 1, 2025 HOUSTON , March 7, 2025 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) (the "Company") is pleased to announce that its Board of Directors has declared a regular quarterly cash dividend of $0.35 per share for the second quarter of 2025 payable in May 2025. Second Quarter 2025 Regular Quarterly Dividend Declared Record Date Payment Date Amount Per Share 3/6/2025 3/31/2025 5/1/2025 $0.35 In addition to the regular quarterly dividend for the second quarter of 2025, the Board of Directors declared a supplemental quarterly cash dividend of $0.01 per share payable in May 2025.
Total Commitments Increased $80.0 million to $245.0 million Accordion Feature Increased $100.0 million to $300.0 million HOUSTON , March 4, 2025 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) (the "Company") is pleased to announce the amendment of its senior secured revolving credit facility (the "Corporate Facility"). The recently closed amendment provides an increase in total commitments from $165.0 million to $245.0 million.
Call Scheduled for 10:00 a.m. Eastern Time on Thursday, March 20, 2025 HOUSTON , Feb. 20, 2025 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) (the "Company") is pleased to announce that it will release its fourth quarter and full year 2024 results on Wednesday, March 19, 2025 after the financial markets close.
MELVILLE, N.Y. and DAVIDSON, N.C.
Underwriters Fully Exercise Option to Purchase Additional Shares HOUSTON , Feb. 4, 2025 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) ("MSC Income" or the "Company"), an externally managed business development company, is pleased to announce that it closed the previously announced public offering of 5,500,000 shares of its common stock (the "Common Stock") at the public offering price of $15.53 per share. MSC Income's shares of Common Stock began trading on the New York Stock Exchange on January 29, 2025 under the ticker symbol "MSIF.
HOUSTON , Jan. 30, 2025 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") is pleased to announce that MSC Income Fund, Inc. ("MSC Income"), an externally managed business development company ("BDC") for which Main Street's wholly owned registered investment adviser, MSC Adviser I, LLC ("MSC Adviser"), serves as the investment adviser and administrator, recently closed a follow-on public offering of 5,500,000 shares of its common stock at $15.53 per share and, in connection with the offering, MSC Income's shares of common stock began trading on the New York Stock Exchange on January 29, 2025 under the ticker symbol "MSIF." MSC Income received gross proceeds from the offering of approximately $85.4 million, which it intends to use, after the fees and expenses associated with the offering, to repay outstanding debt borrowed under its credit facilities, and then through re-borrowing under the credit facilities, to make investments in accordance with its investment objective and strategies, pay operating expenses and other cash obligations, and for general corporate purposes.
HOUSTON , Jan. 28, 2025 /PRNewswire/ -- MSC Income Fund, Inc. ("MSC Income" or the "Company"), an externally managed business development company, today announced that it priced its public offering of 5,500,000 shares of its common stock (the "Common Stock") at $15.53 per share. MSC Income's shares of Common Stock are expected to begin trading on the New York Stock Exchange on January 29, 2025 under the symbol "MSIF.
MELVILLE, N.Y. and DAVIDSON, N.C.
MSC Industrial Direct Co., Inc. MSM will release its first-quarter financial results, before the opening bell, on Wednesday, Jan. 8, 2025.
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. RYONCIL is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents and teenagers.